BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chien Y, Liu C, Shan J, Lee H, Hsieh MH, Hwu H, Chiou L. Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms. Psychoneuroendocrinology 2015;53:1-9. [DOI: 10.1016/j.psyneuen.2014.12.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Öz P, Kaya Yertutanol FD, Gözler T, Özçetin A, Uzbay IT. Lesions of the paraventricular thalamic nucleus attenuates prepulse inhibition of the acoustic startle reflex. Neurosci Lett 2017;642:31-6. [PMID: 28137649 DOI: 10.1016/j.neulet.2017.01.056] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
2 Demidova A, Kahl E, Fendt M. Orexin deficiency affects sensorimotor gating and its amphetamine-induced impairment. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2022. [DOI: 10.1016/j.pnpbp.2022.110517] [Reference Citation Analysis]
3 Tsuchimine S, Hattori K, Ota M, Hidese S, Teraishi T, Sasayama D, Hori H, Noda T, Yoshida S, Yoshida F, Kunugi H. Reduced plasma orexin-A levels in patients with bipolar disorder. Neuropsychiatr Dis Treat 2019;15:2221-30. [PMID: 31496705 DOI: 10.2147/NDT.S209023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
4 Phillips WA, Larkum ME, Harley CW, Silverstein SM. The effects of arousal on apical amplification and conscious state. Neurosci Conscious 2016;2016:niw015. [PMID: 29877512 DOI: 10.1093/nc/niw015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
5 Öz P, Gökalp HK, Göver T, Uzbay T. Dose-dependent and opposite effects of orexin A on prepulse inhibition response in sleep-deprived and non-sleep-deprived rats. Behav Brain Res 2018;346:73-9. [PMID: 29237551 DOI: 10.1016/j.bbr.2017.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Garcia-Rizo C. Antipsychotic-Induced Weight Gain and Clinical Improvement: A Psychiatric Paradox. Front Psychiatry 2020;11:560006. [PMID: 33240120 DOI: 10.3389/fpsyt.2020.560006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Lu J, Huang ML, Li JH, Jin KY, Li HM, Mou TT, Fronczek R, Duan JF, Xu WJ, Swaab D, Bao AM. Changes of Hypocretin (Orexin) System in Schizophrenia: From Plasma to Brain. Schizophr Bull 2021;47:1310-9. [PMID: 33974073 DOI: 10.1093/schbul/sbab042] [Reference Citation Analysis]
8 Liu Z, Zhang Y, Zhao T, Wang J, Xia L, Zhong Y, Yang Y, Ning X, Zhang Y, Ren Z, Liu H. A higher body mass index in Chinese inpatients with chronic schizophrenia is associated with elevated plasma orexin-A levels and fewer negative symptoms. Nordic Journal of Psychiatry 2020;74:525-32. [DOI: 10.1080/08039488.2020.1755995] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Li SB, Jones JR, de Lecea L. Hypocretins, Neural Systems, Physiology, and Psychiatric Disorders. Curr Psychiatry Rep 2016;18:7. [PMID: 26733323 DOI: 10.1007/s11920-015-0639-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
10 Lu J, Li S, Li H, Mou T, Zhou L, Huang B, Huang M, Xu Y. Changes In Plasma NPY, IL-1β And Hypocretin In People Who Died By Suicide. Neuropsychiatr Dis Treat 2019;15:2893-900. [PMID: 31632037 DOI: 10.2147/NDT.S219962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Tsuneki H, Wada T, Sasaoka T. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders. Pharmacology & Therapeutics 2018;186:25-44. [DOI: 10.1016/j.pharmthera.2017.12.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chen PY, Chang CK, Chen CH, Fang SC, Mondelli V, Chiu CC, Lu ML, Hwang LL, Huang MC. Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome. J Formos Med Assoc 2022:S0929-6646(22)00110-3. [PMID: 35396156 DOI: 10.1016/j.jfma.2022.03.008] [Reference Citation Analysis]
13 Katzman MA, Katzman MP. Neurobiology of the Orexin System and Its Potential Role in the Regulation of Hedonic Tone. Brain Sciences 2022;12:150. [DOI: 10.3390/brainsci12020150] [Reference Citation Analysis]
14 Robertson I, Cheung A, Fan X. Insomnia in patients with schizophrenia: current understanding and treatment options. Prog Neuropsychopharmacol Biol Psychiatry 2019;92:235-42. [PMID: 30707986 DOI: 10.1016/j.pnpbp.2019.01.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
15 Kumari V, Ettinger U. Controlled sleep deprivation as an experimental medicine model of schizophrenia: An update. Schizophr Res 2020;221:4-11. [PMID: 32402603 DOI: 10.1016/j.schres.2020.03.064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Bioque M, González-Rodríguez A, Garcia-Rizo C, Cobo J, Monreal JA, Usall J, Soria V, Labad J; PNECAT Group. Targeting the microbiome-gut-brain axis for improving cognition in schizophrenia and major mood disorders: A narrative review. Prog Neuropsychopharmacol Biol Psychiatry 2021;105:110130. [PMID: 33045322 DOI: 10.1016/j.pnpbp.2020.110130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Luckhoff H, Phahladira L, Scheffler F, Asmal L, du Plessis S, Chiliza B, Kilian S, Emsley R. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months. Schizophrenia Research 2019;206:171-6. [DOI: 10.1016/j.schres.2018.11.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
18 Lis M, Stańczykiewicz B, Liśkiewicz P, Misiak B. Impaired hormonal regulation of appetite in schizophrenia: A narrative review dissecting intrinsic mechanisms and the effects of antipsychotics. Psychoneuroendocrinology 2020;119:104744. [DOI: 10.1016/j.psyneuen.2020.104744] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
19 Steward T, Mestre-Bach G, Granero R, Sánchez I, Riesco N, Vintró-Alcaraz C, Sauchelli S, Jiménez-Murcia S, Agüera Z, Fernández-García JC, Garrido-Sánchez L, Tinahones FJ, Casanueva FF, Baños RM, Botella C, Crujeiras AB, Torre R, Fernández-Real JM, Frühbeck G, Ortega FJ, Rodríguez A, Menchón JM, Fernández-Aranda F. Reduced Plasma Orexin-A Concentrations are Associated with Cognitive Deficits in Anorexia Nervosa. Sci Rep 2019;9:7910. [PMID: 31133733 DOI: 10.1038/s41598-019-44450-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
20 Bicakci AO, Tsai PL, Kahl E, Mayer D, Fendt M. Dissociative Effects of Neuropeptide S Receptor Deficiency and Nasal Neuropeptide S Administration on T-Maze Discrimination and Reversal Learning. Pharmaceuticals (Basel) 2021;14:643. [PMID: 34358069 DOI: 10.3390/ph14070643] [Reference Citation Analysis]
21 Tang S, Huang W, Lu S, Lu L, Li G, Chen X, Liu X, Lv X, Zhao Z, Duan R, Du Y, Tang J. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides 2017;88:55-61. [PMID: 27988352 DOI: 10.1016/j.peptides.2016.12.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
22 Chen PY, Chen CH, Chang CK, Kao CF, Lu ML, Lin SK, Huang MC, Hwang LL, Mondelli V. Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics. Int J Neuropsychopharmacol 2019;22:28-36. [PMID: 30204875 DOI: 10.1093/ijnp/pyy075] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Sun HQ, Li SX, Chen FB, Zhang Y, Li P, Jin M, Sun Y, Wang F, Mi WF, Shi L, Yue JL, Yang FD, Lu L. Diurnal neurobiological alterations after exposure to clozapine in first-episode schizophrenia patients. Psychoneuroendocrinology 2016;64:108-16. [PMID: 26630391 DOI: 10.1016/j.psyneuen.2015.11.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
24 Singh R, Bansal Y, Medhi B, Kuhad A. Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol 2019;844:231-40. [PMID: 30529195 DOI: 10.1016/j.ejphar.2018.12.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
25 Craddock KES, Zhou X, Liu S, Gochman P, Dickinson D, Rapoport JL. Symptom dimensions and subgroups in childhood-onset schizophrenia. Schizophr Res 2018;197:71-7. [PMID: 29146021 DOI: 10.1016/j.schres.2017.10.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
26 Ni P, Tian Y, Gu X, Yang L, Wei J, Wang Y, Zhao L, Zhang Y, Zhang C, Li L, Tang X, Ma X, Hu X, Li T. Plasma neuropeptides as circulating biomarkers of multifactorial schizophrenia. Compr Psychiatry 2019;94:152114. [PMID: 31401216 DOI: 10.1016/j.comppsych.2019.152114] [Reference Citation Analysis]